(Q34741259)

4 August 2017

title

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors (English)

1 reference

4 August 2017

Patricia M LoRusso

1

1 reference

4 August 2017

Shirish M Gadgeel

2

1 reference

4 August 2017

Antoinette Wozniak

3

1 reference

4 August 2017

Alan J Barge

4

1 reference

4 August 2017

Helen K Jones

5

1 reference

4 August 2017

Zachary S DelProposto

6

1 reference

4 August 2017

Pamela A DeLuca

7

1 reference

4 August 2017

Jeffrey L Evelhoch

8

1 reference

4 August 2017

Scott A Boerner

9

1 reference

4 August 2017

Catherine Wheeler

10

1 reference

4 August 2017

publication date

25 January 2008

1 reference

Investigational New Drugs

4 August 2017

published in

1 reference

4 August 2017

volume

26

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

159-167

1 reference

ZD6126: a novel small molecule vascular targeting agent

4 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-008-9112-9

Augmentation of radiation response with the vascular targeting agent ZD6126.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-008-9112-9

Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.

21 January 2018

1 reference

12 December 2020

ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

1 reference

12 December 2020

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

1 reference

12 December 2020

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging

1 reference

12 December 2020

Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

1 reference

12 December 2020

Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.

1 reference

12 December 2020

ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.

1 reference

12 December 2020

Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126

1 reference

12 December 2020

Vascular attack as a therapeutic strategy for cancer

1 reference

12 December 2020

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

1 reference

12 December 2020

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors

1 reference

12 December 2020

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

1 reference

12 December 2020

Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange

1 reference

12 December 2020

The endothelial cytoskeleton: organization in normal and regenerating endothelium

1 reference

12 December 2020

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

1 reference

12 December 2020

Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy

1 reference

12 December 2020

The role of angiogenesis in tumor growth

1 reference

12 December 2020

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

1 reference

12 December 2020

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

1 reference

12 December 2020

10.1007/S10637-008-9112-9

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1029579791

0 references

Fatcat ID

release_hatcaxrk55egvf553bvmcfv3dm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hatcaxrk55egvf553bvmcfv3dm

24 November 2022

mapped directly with Wikidata item

1 reference